GBCI vs MTG

GBCI presents a stark contrast between aggressive growth and deteriorating fundamental health, highlighted by a weak Piotroski F-Score of 2/9. While the company exhibits impressive YoY revenue growth of 41.4% and earnings growth of 31.1%, the underlying financial health metrics are concerning. The stock currently trades at a premium to its Graham Number ($38.1) but below its growth-based intrinsic value ($58.7). The high dividend payout ratio of 82.91% combined with a bearish technical trend suggests limited immediate upside despite analyst 'buy' recommendations.

MTG presents a classic deep-value opportunity, characterized by a stable Piotroski F-Score of 4/9 and a significant valuation discount, trading at $29.13 against a Graham Number of $40.72 and an Intrinsic Value of $40.35. The company exhibits exceptional operational efficiency with a 60.84% profit margin and a rock-solid balance sheet (Debt/Equity of 0.13). While revenue growth is stagnant and insider sentiment is bearish, the consistent track record of earnings beats over 25 quarters suggests a highly disciplined management team. The bullish outlook is driven by the massive margin of safety provided by the current price relative to defensive fair value.